In addition, MEK inhibitor as a melanoma treatment is now attractive for the treatment of non–small cell lung carcinoma (NSCLC) for its anti-cancer activity in patients with NSCLC (73). Here, MAP2K7 is linked to non-small cell lung carcinoma.